RASDEGAFUSP ALFA
Recurrent Gastric Carcinoma
Roswell Park Cancer Instituteprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
49 Active assets in the Recurrent Gastric Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan City of Hope Medical Center | Phase 1/2 | CCC |
gsk1120212 National Cancer Institute (NCI) | Phase 2 | CCC |
Dabrafenib National Cancer Institute (NCI) | Phase 2 | CCC |
Trastuzumab Emtansine National Cancer Institute (NCI) | Phase 2 | CCC |
TRASTUZUMAB National Cancer Institute (NCI) | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
RASDEGAFUSP ALFA is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →